Sarcoma Oncology Research Center, LLC
10 clinical trials · Sponsor
◉ Watch Sarcoma Oncology Research Center, LLC
| Record | Firm | Date |
|---|---|---|
| Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors (NCT07671534) | Sarcoma Oncology Research Center, LLC | 2026-06-01 |
| A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma (NCT06494787) | Sarcoma Oncology Research Center, LLC | 2024-08-01 |
| Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures (NCT05869994) | Sarcoma Oncology Research Center, LLC | 2023-01-27 |
| GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma (NCT04535713) | Sarcoma Oncology Research Center, LLC | 2020-09-30 |
| SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma (NCT03778996) | Sarcoma Oncology Research Center, LLC | 2020-01-03 |
| Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors (NCT04165330) | Sarcoma Oncology Research Center, LLC | 2019-10-17 |
| Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (NCT03886311) | Sarcoma Oncology Research Center, LLC | 2019-05-15 |
Track Sarcoma Oncology Research Center, LLC automatically
Every clearance here is in the API, with alerts when new ones post.